Hepatitis C and Pasteurised Factor VIII and IX Concentrates

• References

• 1 Mannucci PM. Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates. Vox Sang 1993; 64: 197-203
• 2 Kreuz W, Auerswald G, Brückmann C, Zieger B, Linde R, Funk M, Auberger K, Sutor AH, Rasshofer R, Roggendorf M. Prevention of hepatitis C virus infection in children with haemophilia A and B and von Willebrand's disease. Thromb Haemost 1992; 67 (01) 184
• 3 Kudesia G, Chapman S, Makris M, Preston FE. Need for second-generation anti-HCV testing in haemophilia. Lancet 1992; 339: 501-502
• 4 Zaaijer HL, Cuypers HT M, Reesink HW, Lelie PN, Vrielink H, van der Poel CL. New immunoblot resolves indeterminate results for antibody to hepatitis C virus. Transfusion 1994; 34: 184
• 5 Gerritzen A, Schneweis K, Scholt B, Brackmann H, Kaiser R, Oldenburg I. Acute hepatitis C in hemophiliacs due to “virus-inactivated” clotting factor concentrates. Thromb Haemost 1992; 68 (06) 781
• 6 Schulman S, Lindgren A, Petrini P, Allander T. Transmission of hepatitis C with pasteurised factor VIII. Lancet 1992; 340: 305-306
• 7 Mannucci P, Schimpf K, Brettler D, Ciavarella N, Colombo M, Haschke F, Lechner K, Lusher J, Weissbach G. The International Study Group Low risk for hepatitis C in hemophiliacs given a high-purity pasteurized factor VIII concentrate. Ann Int Med 1990; 113: 27-32
• 8 Pollmann H, Richter H. Prevalence of hepatitis and HIV in a group of hemophiliacs. Ann Hematol 1994; 68: 128